PCOS is a common, lifelong hormonal disorder that affects 5-10% of women. It is diagnosed when a woman exhibits two of three criteria - irregular periods, high androgen levels, or the presence of cysts on the ovaries. The exact causes are unknown but involve genetic and environmental factors. Symptoms include irregular periods, acne, excess hair growth, and infertility. Long term risks include diabetes, endometrial cancer, and heart disease. Current treatments focus on managing symptoms through lifestyle changes, medication, and fertility treatments, but a cure has not yet been discovered. Research aims to better understand the genetic and molecular underpinnings of PCOS to develop more targeted therapies.
Call Girls ITPL Just Call 7001305949 Top Class Call Girl Service Available
Understanding the Genetics and Treatment of Polycystic Ovarian Syndrome (PCOS
1. Polycystic ovarian syndrome
• Presented by : Simran Shabir
• MSc Biotechnology (2nd Sem)
• Roll no. : 04
• Presented to : Dr Anita Yadav
KURUKSHETRA UNIVERSITY, HARYANA
PCOS
2. • Introduction
• Prevalence
• Diagnosis
• Pathophysiology
• Clinical presentations
• Syndromes associated long term complications
• Hormonal diagnosis
❖ Biotechnology and PCOS
• Paper 1
• Paper 2
• Paper 3
• Conclusion
• References
3. • PCOS is a lifelong multifactorial disorder where
➢Individual genes
➢Gene-gene interaction or
➢Gene-environment interactions
have been reported to influence pre-disposition to PCOS
development.
4. • The worldwide prevalence of PCOS is estimated to be 5-10%.
• Association of PCOS with infertility is 40%.
• A significant difference was noted in white and black females, i.e.,
8% and 4%, respectively in Caucasian and Black races.
• PCOS is also quite prevalent in Indian females of reproductive age,
at nearly 9.13%
PCOS is diagnosed by criteria set by the National Institutes of Health (NIH) in 1990 and the estimation of the
prevalence of PCOS depends on how many of the criteria were followed.
Prevalence
5. 1) Oligomenorrhea or anovulatory cycle
Clinical or biochemical
2) Hyperandrogenism
•Acne
•Hirsutism
•Elevated Sr. Testosterone levels
3) USG --> 12 follicles (2-9 mm diameter)
arranged peripherally
Rotterdam criteria
Any 2 positive criteria indicates PCOS
Diagnosis of PCOS
17. Long term complications associated with
PCOS
Diabetes mellitus type (II)
Endometrial hyperplasia &Endometrial carcinomas
Breast carcinoma
Osteoporosis
Cardiovascular diseases
Syndrome X
Hypertension
30. Result
14 genes were identified and retrieved from
NCBI and UniProt
8 were up-regulated genes
6 were down-regulated genes
31. • Computational study of genetic disorders like PCOS can be
scrutinised in both
➢Sequential aspect and
➢Structural aspect
to cognise the mechanism of such types of genetic syndrome.
Conclusion
32.
33. Abstract
CYP19A1
gene
Encodes an aromatase enzyme that mediate
conversion of androgens to Estrogen.
3 genetic variants investigated:
Exonic variant – rs700519
Two intronic variants- rs2414096 &
rs60271534
34. Introduction
CYP1PA1 gene encoding aromatase is located on
Chr.15q21.1
Spans more than 123kb –
30kb – coding region
93kb – regulatory region
Nine alternate untranslated exons present in 93kb
gene regulatory region regulate the specificity.
36. Result
1)
• All the 3 gene variants are associated
significantly with disease
susceptibility (p<0.05).
2)
• Exonic variant - Arg264Cys has a
major role in the disease
pathogenicity through its reduced
aromatase activity.
37.
38.
39. 1) Genes involved in Ovarian and Adrenal Steroidogenesis
CYP11a CYP21 CYP17 CYP19
Cholesterol
Progesterone
Enzyme
coded by
CYP11a
17-
hydroxyprogesterone
11-deoxycortisol
Enzyme
coded by
CYP21
Pregnenolone &
progesterone
17-
hydroxypregnelone &
17-
hydroxyprogesterone
Enzyme
coded by
CYP17
Enzyme
aromatase
p450
Formation of
Estrogen
41. Conclusion
PCOS is a life-long disorder.
PCOS is a multi-functionary disorder.
No consensus has been reached on an established genitive
marker for PCOS.
Progress have been achieved in the management and
diagnosis of PCOS ; however, not significant is known about
the molecular players and signalling pathway underlying.